

Case Report

Role of Cardiac Magnetic Resonance in Detecting Biventricular Apical Hypertrophic Cardiomyopathy

Nathan Zaher,¹ Hammam Shereef²,^{ORCID} Rashid Al Hussain,¹ John Dawdy³,^{ORCID} Diane Levine,¹ and M. Chadi Alraies³

¹Department of Internal Medicine, Wayne State University/Detroit Medical Center, Michigan, USA

²Department of Internal Medicine, Beaumont Hospital-Dearborn, Michigan, USA

³Division of Cardiology, Wayne State University/Detroit Medical Center, Michigan, USA

Correspondence should be addressed to Hammam Shereef; hammam.shereef@beaumont.org

Received 22 June 2020; Revised 12 January 2021; Accepted 31 January 2021; Published 10 February 2021

Academic Editor: Luigi Sciarra

Copyright © 2021 Nathan Zaher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Apical Hypertrophic Cardiomyopathy (ApHCM) is a rare variant of hypertrophic cardiomyopathy with a low prevalence in the general population. ApHCM with right ventricular involvement (BiApHCM) is largely unreported and may not be detected with conventional transthoracic echocardiogram (TTE) alone. Cardiac Magnetic Resonance (CMR) has been demonstrated to be a proficient imaging modality to diagnose BiApHCM. We present a case of BiApHCM that was diagnosed with TTE and further characterized by CMR. This imaging modality may be utilized more in the future to help diagnose and detect the prevalence of BiApHCM.

1. Introduction

Apical Hypertrophic Cardiomyopathy (ApHCM) is a rare variant of hypertrophic cardiomyopathy involving the left ventricle. ApHCM with right ventricular (RV) involvement (BiApHCM) is largely unreported and may not be detected with transthoracic echocardiogram (TTE). Cardiac Magnetic Resonance Imaging (C-MRI) has superior sensitivity and provides additional important details related to cardiac thickness and function. We herein present a case of BiApHCM that was diagnosed with TTE and further characterized by C-MRI. This imaging modality provides superior quality and may be considered for screening purposes in appropriately selected patients with clinically suggestive findings and negative echocardiograms. It has also been shown to be a better determinate of LV wall thickness which has a significant impact on management decisions and patient outcomes.

2. Case Description

A 55-year-old man presented to the Emergency Department (ED) with palpitations, shortness of breath, and nonexertional pleuritic chest pain and was found to be in atrial fibrillation. His vitals were stable, and there was a systolic grade 3/6 murmur loudest at the left sternal border on physical exam. A 12-lead EKG was obtained and revealed underlying atrial fibrillation rhythm with increased voltage criteria of left ventricular hypertrophy and right bundle branch block with RSR pattern in V2 and V4 (Figure 1). A TTE was ordered and demonstrated hyperdynamic systolic function and exuberant apical hypertrophy with right ventricular involvement (Figure 2). Offline longitudinal strain analysis was performed at appropriate frame rates and was consistent with BiApHCM (Figure 3). A C-MRI, without and with contrast, demonstrated nonobstructive cardiomyopathy with RV thickening (Figures 4–6). The thickening was pronounced




FIGURE 1: 12-lead EKG showed absence of *P* wave, baseline fibrillary waves, increased LVH by Sokolow-Lyon criteria, and RSR pattern in V2 and V3.




FIGURE 2: 2D echocardiography parasternal long-axis view in diastole (a) and systole (b) along with apical 4-chamber view in diastole (c) and systole (d) showing apical hypertrophy in both left and right ventricles (first attachment).

in the midapical area with a wall measurement of 6.5 ± 1.3 mm at the midapical segment. The patient was managed with metoprolol both for rate control of atrial fibrillation and to maximize diastolic filling time and cardiac output. He was instructed to follow-up as an outpatient for genotyping/cascade screening.

3. Discussion

Apical Hypertrophic Cardiomyopathy (ApHCM), a rare form of HCM, manifests as hypertrophy of the left ventricular apex and has nonobstructive physiology. Research has found sarcomere mutations can cause apical hypertrophy,




FIGURE 4: (a) Severe concentric left ventricular hypertrophy with focal maximum thickness of myocardium 20 mm in the mid anterior wall. (b) Globally hyperdynamic left ventricular systolic function with calculated LV EF 80% and near obliteration of mid and distal segments in systole.




FIGURE 5: MRI short-axis view showing mid-LV chamber at the end of diastole (a) with obliteration of cavity in end systole (b). MRI short-axis view showing apex in end diastole (c) with obliteration of cavity in systole (d). Hypertrophy can be appreciated in both the left and right ventricles.




FIGURE 6: A 4-chamber long axis inversion recovery showing late gadolinium enhancement in the apex.

Patient presentation and approach to treatment in BiApHCM are similar to that of left-sided ApHCM. First-line therapy is an AV nodal blocking agent. Those who remain symptomatic can be offered resection of accessory RV muscles in the outflow tract [4, 5]. Despite being the most sensitive and accurate imaging modality for BiApHCM, C-MRI has not been widely obtained due to cost-related limitations [6]. One study involving 330 myocardial segments showed that thickness could be measured by echocardiography in 221 (67%) vs. 320 (97%) with C-MRI. Reliance on routine echocardiography as the sole imaging modality to rule out ApHCM has led to underreporting of this condition

with potentially suboptimal outcomes [7]. This is also of important clinical significance as patients with massive LVH (>30 mm) are often considered high risk and should be considered for ICD therapy [8].

Conflicts of Interest

None of the authors have any conflicts of interest to declare.

References

- [1] M. Arad, M. Penas-Lado, L. Monserrat et al., “Gene mutations in apical hypertrophic cardiomyopathy,” *Circulation*, vol. 112, no. 18, pp. 2805–2811, 2005.
- [2] A. M. H. Ho, P. T. Chui, A. P. W. Lee, and S. Wan, “Hypertrophic cardiomyopathy apical variant,” *Cleveland Clinic Journal of Medicine*, vol. 81, no. 9, pp. 517–519, 2014.
- [3] T. Doctorian, W. J. Mosley, and B. Do, “Apical hypertrophic cardiomyopathy: case report and literature review,” *American Journal of Case Reports*, vol. 18, pp. 525–528, 2017.
- [4] H. Sanoussi, N. Kourireche, L. Oukerraj, and M. Cherti, “Right ventricle outflow obstruction in biventricular hypertrophic cardiomyopathy in amyloidosis,” 2017, <https://www.ejcrim.com/index.php/EJCRIM/article/view/733>.
- [5] X. Guo, C. Fan, L. Tian, and Y. Liu, “Abstract 12176: outcomes and genetic characteristics of hypertrophic cardiomyopathy with severe right ventricular hypertrophy,” 2017, https://www.ahajournals.org/doi/abs/10.1161/circ.132.suppl_3.1217.
- [6] S. Cardozo, “‘International+Journal+of+Cardiology’[Jour] - PubMed - NCBI.” National Center for Biotechnology Information, U.S. National Library of Medicine,” 2016, [http://www.ncbi.nlm.nih.gov/pubmed?term=International+journal+of+cardiology\[Jour\]&cmd=detailssearch](http://www.ncbi.nlm.nih.gov/pubmed?term=International+journal+of+cardiology[Jour]&cmd=detailssearch).
- [7] G. Pons-Lladó, F. Carreras, X. Borrás, J. Palmer, J. Llauger, and A. Bayés de Luna, “Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging,” *The American Journal of Cardiology*, vol. 79, no. 12, pp. 1651–1656, 1997.
- [8] M. S. Maron, I. Olivotto, S. Betocchi et al., “Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic Cardiomyopathy,” *New England Journal of Medicine*, vol. 348, no. 4, pp. 295–303, 2003.